Using Health-related Quality of Life (HRQL) in Routine Clinical Care

This study has been completed.
Sponsor:
Collaborators:
Institute of Health Economics, Canada
Roche Pharma AG
Information provided by:
University of Alberta
ClinicalTrials.gov Identifier:
NCT00457301
First received: April 4, 2007
Last updated: September 21, 2009
Last verified: August 2009
  Purpose

The objective of this study is to assess the effects of using HRQL measures in the clinical care of pre- and post-lung transplant patients.

The hypotheses are that the inclusion of HRQL measures, the Health Utilities Index System Mark 2(HUI2) and Mark 3 (HUI3), in routine clinical care of pre- and post-lung transplant patients, will: 1) improve patient-clinician communication;2) affect patient management; 3) improve patients' HRQL.


Condition Intervention
Chronic Obstructive Pulmonary Disease
Pulmonary Fibrosis
Pulmonary Hypertension
Cystic Fibrosis
Behavioral: HUI score card

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Health Services Research
Official Title: An Assessment of the Effects of the Use of Measures of Health-related Quality of Life in Routine Clinical Care:an Application to Lung Transplantation.

Resource links provided by NLM:


Further study details as provided by University of Alberta:

Primary Outcome Measures:
  • Communication Score [ Time Frame: Baseline and end of study (6 months) ] [ Designated as safety issue: No ]
  • Management Composite [ Time Frame: At baseline and end of study (6 months) ] [ Designated as safety issue: No ]
  • EuroQol, EQ-5D. [ Time Frame: At baseline and end of study (6 months). ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The Hospital Anxiety and Depression Scale,HADS. Completed at Baseline and End of the Study. [ Time Frame: Baseline and end of study (6 months) ] [ Designated as safety issue: No ]

Enrollment: 213
Study Start Date: July 2005
Study Completion Date: May 2008
Primary Completion Date: April 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Control Behavioral: HUI score card
Patients completed the HUI2 and HUI3 before the encounter with the clinician, the result was graphically represented in the HUI score card. Clinicians used the HUI score card as an extra tool to help them in the management of the patients
Other Name: Health Utilities Index Score Card

Detailed Description:

Recently there has been increasing interest in the use of health-related quality of life (HRQL) measures in routine clinical practice. Traditionally, patient care has been based on laboratory results, medical history, and signs and symptoms diagnosed by clinicians. The inclusion of HRQL measures in routine practice may provide important and often otherwise missing information, revealing the impact of the disease or its treatment on the patient's physical, emotional and social well-being, and may assist in patient management. HRQL assessments may assist in changing the medical paradigm from a disease-centered approach to a patient-centered one.

Several studies in mental health and oncology discuss the application of HRQL measures in clinical practice. Taenzer et al (2000) and Detmar et al. (2002) provide evidence that using HRQL measures improves patient-clinician communication. Velikova et al (2004) detected impacts on communication and the emotional well-being of patients.

Using a framework based on these previous studies and the methods for the health technology assessment of diagnostic technologies (Guyatt et al. 1986), we will assess the effects of including HRQL assessments in the routine clinical care of patients undergoing solid organ transplantation (lung).

We expect that the routine use of HRQL measures in clinical practice will affect patient-clinician communication, patient management, and patient outcome.

Lung transplantation trades a fatal disease (end-stage pulmonary disease) for a chance at prolonged survival and improved quality of life, albeit with immunosuppression. In this context, generic preference-based measures such as HUI2 and HUI3 are preferred to specific measures, because they measure a broader range of health dimensions, including pain, ambulation and emotional issues that are expected to be relevant. Preference-based measures provide scores on the conventional 0.00 (dead) to 1.00 (perfect health) scale that allows for the integration of morbidity and mortality effects and calculation of quality adjusted life years (QALYs) and health-adjusted life expectancy (HALE).

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • pre-lung transplant:subjects who are included on the waiting list and are being seen at the out-patient clinic
  • post-lung transplant subjects.

Exclusion Criteria:

  • younger than 18 years of age
  • diagnosed as being cognitively impaired
  • unable to complete questionnaires in English
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00457301

Locations
Canada, Alberta
University of Alberta Hospital
Edmonton, Alberta, Canada
Sponsors and Collaborators
University of Alberta
Institute of Health Economics, Canada
Roche Pharma AG
Investigators
Principal Investigator: David H Feeny, PhD Professor Economics, University of Alberta
  More Information

No publications provided

Responsible Party: Maria Jose Santana, Lung transplant program University of Alberta Hospital
ClinicalTrials.gov Identifier: NCT00457301     History of Changes
Other Study ID Numbers: IHE-188
Study First Received: April 4, 2007
Results First Received: April 15, 2009
Last Updated: September 21, 2009
Health Authority: Canada: Health Canada

Keywords provided by University of Alberta:
Lung transplantation, health-related quality of life.

Additional relevant MeSH terms:
Cystic Fibrosis
Fibrosis
Hypertension
Hypertension, Pulmonary
Lung Diseases
Respiration Disorders
Pulmonary Disease, Chronic Obstructive
Pulmonary Fibrosis
Lung Diseases, Obstructive
Pancreatic Diseases
Digestive System Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Pathologic Processes
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on April 22, 2014